Literature DB >> 364571

Elimination and organ distribution of intravenously administered allogeneic and xenogeneic IgG modifications. (Standard IgG, F (ab)2-fragments and beta-propiolactone treated IgG) in dogs.

J Ring, K H Duswald, T Bachmann, J von Scheel, W Stephan, W Brendel.   

Abstract

Dog IgG was produced by fractionation procedures used for the production of clinically used i.v. gammaglobulins. Chemical modification of dog IgG was done by pepsin or beta-propiolactone treatment. The intravascular half-life of beta-propiolactone IgG was 8.5 +/- 2.1 days compared to 4.5 +/- 1.6 days of pepsin treated IgG. Tissue concentrations of radioactive labelled beta-propiolactone IgG were generally higher than of pepsin digested IgG. Pepsin treated Igg was degraded to a significantly higher extent (26% of the administered radioactivity was bound to fragments smaller than 6000 MW after three days) than beta-propiolactone IgG (9% fragments after the same interval, P less than 0.001). It is concluded that the short intravascular half-life of pepsin IgG cannot be explained by increased extravascular filling, but is due to rapid degradation and excretion via the kidneys. There was no obvious difference in elimination and organ distribution between standard and beta-propiolactone IgG.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 364571     DOI: 10.1007/bf01851492

Source DB:  PubMed          Journal:  Res Exp Med (Berl)        ISSN: 0300-9130


  2 in total

1.  Effect of von Willebrand factor on the pharmacokinetics of recombinant human platelet glycoprotein Ibalpha-immunoglobulin G1 chimeric proteins.

Authors:  Qin Wang; Douglas Shorten; Xin Xu; Gray D Shaw; Robert G Schaub; Christopher Shea; Jonathan Brooks; Dianne Sako; Erin Wiswall; Jin Xu; Pamela Szklut; Vikram S Patel
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

2.  [Problems of intravenous gammaglobulin therapy (author's transl)].

Authors:  J Ring; K H Duswald
Journal:  Klin Wochenschr       Date:  1980-08-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.